Sexual and reproductive health
PT-141
Also called Bremelanotide
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US.
Quick start
PT-141 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 0.5–2 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~14 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C50H68N14O10
- Mol. weight
- 1,025.2 Da
- CAS
- 189691-06-3
- PubChem CID
- 9941379
External references
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for PT-141 describe 0.5–2 mg per administration. Descriptive only, not a recommendation.
Dosing schedule
How PT-141 is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| As neededA melanocortin agonist used episodically, not on a standing daily schedule. Nausea is dose-limiting. | 0.5–2 mg | Up to once in 24 h, a few hours before | SubQ |
What it can be combined with
How PT-141 is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- Melanotan-1 (MT-1)Both are melanocortin-receptor agonists, so together they compound the same effects, including nausea.Use caution
- Melanotan-2 (MT-2)Both are melanocortin-receptor agonists, so combining them intensifies shared effects such as nausea and flushing.Use caution
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 0.96× single dose
- Time to steady state
- 14hours
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Bremelanotide (Vyleesi) programA melanocortin-receptor agonist studied for sexual-desire indications.